Capella BioScience

Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics for oncology and autoimmune disease, enabling researchers to research the latest medical technology-based drugs.

Lux Capital

🏥 Healthcare